
Years of research and dozens of papers probing PET’s might in staging lymphoma have yielded sizable data showing that it does not supersede bone marrow biopsy. Clinicians who choose to replace biopsy with FDG-PET could potentially miss a high number of cases of infiltrative disease, according to a study published in the June issue of the Journal of Nuclear Medicine.























